A fast, scalable platform for decoding tens of millions of cells from patient samples
Official title: A Uniquely Scalable Platform for Sequencing Tens of Millions of Single Cells from Complex Clinical Samples with a Streamlined Workflow
Funded at Sansimeon, INC · NIH-11389440 · Data updated 2026-11-12
A new high-throughput system helps scientists study very large numbers of cells from patient blood and tumor samples to improve cancer care.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sansimeon, INC NIH-funded |
| Lab location | 1 site (Fremont, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,129,755 |
| NIH project number | 5R44GM149003-03 |
| Project ID | NIH-11389440 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include patients with cancer or other diseases where tissue or blood samples can be analyzed at the single-cell level for diagnostics or therapy planning.
✕Less likely to help
Patients whose samples cannot be processed by the platform or who are not undergoing procedures that yield suitable tissues may not receive direct benefits.
What this research studies
This project aims to streamline single-cell sequencing so clinicians and researchers can process large patient-derived samples quickly and reliably. It combines automated workflows and advanced microfluidics to preserve cells’ natural states while handling peripheral blood and tissue dissociations. The platform will include user-friendly computational tools to manage big single-cell datasets and support applications in diagnostics, drug discovery, and cancer therapy development. Clinically relevant samples will be used to validate performance and demonstrate real-world utility in healthcare settings.
Why it matters
Potential benefit: If successful, patients could benefit from faster and more detailed cellular analyses that inform personalized cancer treatments and faster drug development.
How similar studies have gone: Previous single-cell sequencing efforts have shown that scalable workflows can enable meaningful insights, but this project aims to push throughput and integration with clinical workflows.
Where this research is happening
-
Sansimeon, INC
Fremont, United States Active
Researchers
- Principal investigator: Spuhler, Philipp Stefan — Sansimeon, INC
- Study coordinator: Spuhler, Philipp Stefan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.